Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (syncytiotrophoblasts) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 78 | 0.91 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 11002
Sealed predictions
- ATG9B in dopamine neurons, braak+0.31 (p 0.411) → -0.67 (p 0.050)receipt 11009
Swarm cases
receipt 11009: ATG9B in dopamine neurons, braak
- power
- full sample -0.28 (p 0.265, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.258, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.35 (p 0.156, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.265, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATG9B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts